Literature DB >> 7972903

Variations in the management and outcome of non-small cell lung cancer in Ontario.

W J Mackillop1, P Dixon, Y Zhou, C T Ago, G Ege, D I Hodson, J F Kotalik, C Lochrin, L Paszat, D Harris.   

Abstract

Prospectively gathered information in the Ontario Cancer Foundation's computerized clinical database was analysed to provide a description of the management of 12,399 patients with unresected non-small cell lung cancer (NSCLC) registered at seven regional cancer centres in Ontario between 1982 and 1991. Overall, 44% received initial thoracic radiotherapy, 19% received initial radiotherapy to metastatic sites, and 36% received no immediate radiotherapy. Of those who received thoracic radiation 41% received doses > or = 40 Gy and 59% received doses < 40 Gy. Among the seven centres, the proportion of patients receiving initial thoracic radiotherapy ranged from 41% to 56% (p < 0.001), and the proportion of those receiving doses > or = 40 Gy ranged from 30% to 68% (p < 0.001). Between 1982 and 1991, the overall proportion of patients who received initial thoracic radiotherapy decreased from 48% to 38%, the proportion of those receiving high dose treatment decreased from 55% to 28%, and the mean number of fractions given to the chest decreased from 17 to 10. Only 10% received chemotherapy at any time, and that proportion ranged from 3% to 21% (p < 0.001) among the seven centres. Between 1982 and 1991 the proportion of patients receiving chemotherapy decreased significantly from 15% to 8% (p < 0.001) across the Cancer Foundation as a whole. These wide variations in management policies were not associated with any significant differences in survival, which was similar at all seven centres, and remained constant between 1982 and 1991.

Entities:  

Mesh:

Year:  1994        PMID: 7972903     DOI: 10.1016/0167-8140(94)90096-5

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

1.  A treatment trade-off based decision aid for patients with locally advanced non-small cell lung cancer.

Authors:  Michael D. Brundage; Deb Feldman-Stewart; Peter Dixon; Richard Gregg; Youssef Youssef; Diane Davies; William J. MacKillop
Journal:  Health Expect       Date:  2000-03       Impact factor: 3.377

2.  Factors Associated With the Use of Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer in Alberta, Canada: A Population-based Study.

Authors:  Hong-Wei Liu; Marc Kerba; Gerald Lim; Zsolt Gabos; Ivo A Olivotto; Anil Abraham Joy; Wilson Roa; Zoann Nugent; Harold Lau
Journal:  Cureus       Date:  2016-10-27

3.  Use of palliative radiotherapy in brain and bone metastases (VARA II study).

Authors:  Jose Expósito; Javier Jaén; Enrique Alonso; Isabel Tovar
Journal:  Radiat Oncol       Date:  2012-08-03       Impact factor: 3.481

4.  Pattern of use of radiotherapy for lung cancer: a descriptive study.

Authors:  Isabel Tovar; Jose Expósito; Javier Jaén; Enrique Alonso; Miguel Martínez; Rosa Guerrero; Juan P Arrebola; Rosario Del Moral
Journal:  BMC Cancer       Date:  2014-09-23       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.